- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06044337
A Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adults With Active Subacute Cutaneous Lupus Erythematosus (CLE) and/or Chronic CLE With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE)
A Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy
The primary objective of the study is to evaluate the long-term safety and tolerability BIIB059 (litifilimab) in participants who completed the parent study 230LE301 (NCT05531565) with active subacute CLE and/or chronic CLE with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.
The secondary objectives of the study are to evaluate the long-term effect of litifilimab on disease activity and the effect of litifilimab in preventing disease damage in participants with active subacute CLE and/or chronic CLE with or without systemic manifestations and refractory and/or intolerant to antimalarials; to evaluate the long-term effect of litifilimab on preventing lupus flare in participants with CLE with systemic lupus erythematosus (SLE); to assess long-term use of oral corticosteroid (OCS) in participants receiving litifilimab treatment; to assess the impact of litifilimab on participant-reported health-related quality of life (HRQoL); to evaluate long-term effect of litifilimab on laboratory parameters; to evaluate the immunogenicity and pharmacokinetics (PK) of litifilimab.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: US Biogen Clinical Trial Center
- Phone Number: 866-633-4636
- Email: clinicaltrials@biogen.com
Study Contact Backup
- Name: Global Biogen Clinical Trial Center
- Email: clinicaltrials@biogen.com
Study Locations
-
-
-
Paris, France, 75020
- Hopital Tenon
-
-
-
-
-
Barcelona, Spain, 8041
- Hospital de la Santa Creu i Sant Pau
-
-
-
-
-
Solna, Sweden, 17000
- Karolinska Universitetssjukhuset - Solna
-
-
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- David Fivenson, MD, Dermatology, PLLC
-
Troy, Michigan, United States, 48084
- Revival Research Institute, LLC
-
-
Texas
-
Grapevine, Texas, United States, 76034
- Precision Comprehensive Clinical Research Solutions
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants who completed the parent study (230LE301 [NCT05531565], Part A or Part B) on study treatment (received treatment through Week 48 and attended the last study assessment visit at Week 52).
- Ability of the participant to understand the purpose and risks of the study, to provide informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations.
Key Exclusion Criteria:
- Early Part A or Part B parent study (230LE301 [NCT05531565]) treatment terminators (participants who discontinued study treatment before Week 48).
- Early Part A or Part B parent study terminators [participants who withdrew from parent study participation before Week 52 and did not complete the parent study extended treatment period (ETP)].
- Participants who have developed any other medical diseases, conditions, or abnormalities, rendering their participation in the long-term extension (LTE) study unsuitable in the opinion of the Investigator.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIIB059
Participants will receive BIIB059 subcutaneously, once every 4 weeks up to Week 100.
|
Administered as specified in the treatment arm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants who Achieve a Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity Score (CLASI)-70 Response, Defined as a 70% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants who Achieve a CLASI-50 Response, Defined as a 50% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants who Achieve a CLASI-90 Response, Defined as a 90% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants who Achieve a CLA-IGA-R Other Morphologic Characteristics (OMC) Score of 0 or 1
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained CLASI-70 Response, Defined as the Number of Weeks With 70% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained CLASI-50 Response, Defined as the Number of Weeks With 50% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained CLASI-90 Response, Defined as the Number of Weeks With 90% Improvement in CLASI-A Score From the Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained Efficacy, Defined as the Number of Weeks With CLA-IGA-R Erythema Score of 0 or 1
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained Efficacy, Defined as the Number of Weeks With CLA-IGA-R OMC Score of 0 or 1 and Improvement of at Least 1 Point From Baseline Value (Parent Study [NCT05531565])
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Cumulative Duration of Sustained Efficacy, Defined as the Number of Weeks With CLA-IGA-R Follicular Activity Score of 0
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants With a CLASI-70 Response Among CLASI-70 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLASI-50 Response Among CLASI-50 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLASI-90 Response Among CLASI-90 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLA-IGA-R Erythema Score of 0 or 1 Among Participants With a CLA-IGA-R Erythema Score of 0 or 1 at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With CLA-IGA-R OMC Score of 0 or 1 and at Least 1 Level of Improvement From Baseline Value(Parent Study) Among Participants With CLA IGA R OMC Score of 0 or 1 and at Least 1 Level Improvement From Baseline Value(Parent Study)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLASI-70 Response Among CLASI-50 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLASI-90 Response Among CLASI-50 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With a CLASI-90 Response Among CLASI-70 Responders at Week 52 of the Parent Study (NCT05531565)
Time Frame: Day 0 (Week 52 of parent study) up to 128 weeks
|
Day 0 (Week 52 of parent study) up to 128 weeks
|
Percentage of Participants With Loss of Response, Defined as an Increase of ≥ 7 Points in CLASI-A Total Score From Baseline
Time Frame: Baseline (Day 0) up to 128 weeks
|
Baseline (Day 0) up to 128 weeks
|
Percentage of Participants With Loss of Response, Defined as Achieving 2 Points Improvement From Baseline Value(Parent Study) CLA-IGA-R Erythema Score at Beginning of/During LTE Study and Then Relapsing to CLA-IGA-R Erythema Baseline Value(Parent Study)
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Percentage of Participants With Loss of Response, Defined as Having at Least 2, 3, and 4 Points Worsening in CLA-IGA-R Erythema Score From Their Minimum Score in Parent Study (NCT05531565)
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Absolute Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index Damage (CLASI-D) Score From the Baseline (Parent Study [NCT05531565]) to Week 104
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Percent Change in CLASI-D Score From the Baseline (Parent Study [NCT05531565]) to Week 104
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Annualized Mild/Moderate and Severe Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index Flare Index (SFI) Rates From Baseline Value (Parent Study [NCT05531565]) Through Week 52
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
Annualized Mild/Moderate and Severe SFI Rates From Baseline Value (Parent Study [NCT05531565]) Through Week 104
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Percentage of Participants With Oral Corticosteroid (OCS) Dose
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Percentage of Participants With OCS ≤ 7.5 Milligrams per day (mg/day)
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Percentage of Participants With OCS ≤ 5.0 mg/day
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Change From Baseline Value (Parent Study [NCT05531565]) in Cutaneous Lupus Erythematosus - Quality of Life (CLE-QoL) at Weeks 52 and 104
Time Frame: Baseline, Weeks 52 and 104
|
Baseline, Weeks 52 and 104
|
Change From Baseline Value (Parent Study [NCT05531565]) in European Quality of Life - 5-Dimensions Questionnaire, 3-Level Version (EQ-5D-3L) at Weeks 52 and 104
Time Frame: Baseline, Weeks 52 and 104
|
Baseline, Weeks 52 and 104
|
Change From Baseline Value (Parent Study [NCT05531565]) in 36-Item Short Form Survey (SF-36) (acute version) at Weeks 52 and 104
Time Frame: Baseline, Weeks 52 and 104
|
Baseline, Weeks 52 and 104
|
Change From Baseline Value (Parent Study [NCT05531565]) in Work Productivity and Activity Impairment (WPAI): Lupus at Weeks 52 and 104
Time Frame: Baseline, Weeks 52 and 104
|
Baseline, Weeks 52 and 104
|
Change From Baseline Value (Parent Study [NCT05531565]) in Patient Health Questionnaire-9 (PHQ-9) at Weeks 52 and 104
Time Frame: Baseline, Weeks 52 and 104
|
Baseline, Weeks 52 and 104
|
Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in Standard Laboratory Parameters
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Number of Participants With Clinically Relevant Change From Baseline Value (Parent Study [NCT05531565]) in ECG Results
Time Frame: Up to 104 weeks
|
Up to 104 weeks
|
Number of Participants With Anti-BIIB059 Antibodies in Serum
Time Frame: Up to 128 weeks
|
Up to 128 weeks
|
Serum Concentration of Litifilimab
Time Frame: Pre-dose up to 128 weeks
|
Pre-dose up to 128 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Biogen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 230LE305
- 2023-504863-17-00 (Other Identifier: EU CTIS Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subacute Cutaneous Lupus Erythematosus
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
Novartis PharmaceuticalsCompletedSubacute Cutaneous Lupus ErythematosusGreece, Germany, Italy
-
Bristol-Myers SquibbActive, not recruitingLupus Erythematosus, Discoid | Lupus Erythematosus, Subacute CutaneousMexico, Argentina, Australia, United States, France, Germany, Poland, Taiwan
-
BiogenCompletedHealthy | Atopic Dermatitis | Discoid Lupus Erythematosus | Subacute Cutaneous Lupus ErythematosusUnited States
-
University of PennsylvaniaRecruitingCutaneous Lupus Erythematosus (CLE)United States
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Gilead SciencesRecruitingCutaneous Lupus Erythematosus (CLE)United States, Spain, Czechia, Germany
-
University of PennsylvaniaCelgene CorporationCompletedCutaneous Lupus Erythematosus (CLE)United States
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
Clinical Trials on BIIB059 (litifilimab)
-
BiogenRecruitingLupus Erythematosus, SystemicUnited States, Australia, Korea, Republic of, Chile, Spain, Poland, Philippines, Taiwan, Greece, Brazil, Bulgaria, Mexico, France, Russian Federation, Sweden
-
BiogenEnrolling by invitationSystemic Lupus Erythematosus (SLE)Spain, Bulgaria, United States, China, Serbia, Mexico, Korea, Republic of, Chile, Argentina, Poland, Japan, Romania, Colombia, Hungary, Czechia, United Kingdom, Taiwan, Brazil, Israel, France
-
BiogenCompletedSystemic Lupus Erythematosus | Active Cutaneous Lupus ErythematosusUnited States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
-
BiogenRecruitingSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Italy, Korea, Republic of, Taiwan, Argentina, Chile, Spain, Canada, Serbia, France, Germany, Japan, Brazil, United Kingdom, Puerto Rico, Bulgaria, Portugal, Switzerland, Philippines, Saudi Arabia, Sweden, Mexico, Poland, Hunga... and more
-
BiogenRecruitingLupus Erythematosus, SystemicChina, United States, Belgium, Netherlands, Japan, Romania, Serbia, Canada, Germany, Hungary, Italy, Puerto Rico, Israel, Argentina, Colombia, Czechia, United Kingdom
-
BiogenCompletedHealthy SubjectsUnited States
-
BiogenCompletedSystemic Lupus Erythematosus | Healthy VolunteersUnited States